Depression is a common depression disorder and a leading cause of disability worldwide, with evidence linking it bidirectionally to cancer and suggesting elevated cancer risk. Its core clinical function in the literature is as the condition being diagnosed, monitored, and treated, including symptom tracking with the Geriatric Depression Scale (GDS ≥ 5), 8-week escitalopram treatment, and psychotherapy approaches such as cognitive behavioral therapy and cbt. Recent work also frames depression as a biologically measurable state associated with higher epigenetic age acceleration, including PCPhenoEAA in Asian older adults, and with brain temporal complexity as a potential neuromarker of antidepressant response. Mechanistically, the cancer-depression literature highlights shared pathways and integrated strategies, including selective serotonin reuptake inhibitors and psychotherapy, while digital mental health interventions are being developed as scalable tools to reduce depressive symptoms. Traditional and experimental studies also report that zhi zi hou po decoction ameliorates depressive-like behaviors via TFAM-induced mitophagy in neurons to alleviate neuroinflammation. Overall, depression is studied across psychiatry, oncology, aging, and digital therapeutics, with recent literature emphasizing both symptom improvement and underlying biological signatures.
Cancer
- Depression is described as bidirectionally associated with cancer, with the literature noting a potential increase in cancer risk and shared mechanisms that may support integrated therapeutic strategies. (PMID:41672225)
- The cancer-depression cycle is discussed in relation to combined use of selective serotonin reuptake inhibitors and psychotherapy, including cbt, as part of integrated care. (PMID:41672225)
- A 2026 Cancer Letters review (PMID:41672225) emphasizes shared mechanisms linking depression and cancer and proposes integrated therapeutic strategies.
- Depression is framed as a clinically relevant comorbidity in oncology because of its bidirectional relationship with cancer. (PMID:41672225)
Biomarkers and Aging
- Depressive symptoms were robustly associated with higher epigenetic age acceleration in Asian older adults, including higher PCPhenoEAA. (PMID:41933070)
- The association was reported for depression, but not anxiety, highlighting specificity for depressive symptoms in aging-related epigenetic measures. (PMID:41933070)
- Brain temporal complexity was evaluated as a novel neuromarker to predict antidepressant treatment effectiveness in depression. (PMID:41452049)
- The CAN-BIND-1 study report (PMID:41452049) suggests temporal complexity may help monitor treatment response during antidepressant therapy.
Treatment and Digital Interventions
- Depression was the condition treated with 8 weeks of escitalopram in a clinical study assessing symptom improvement. (PMID:41452049)
- cognitive behavioral therapy is described as an effective treatment for depression, and cbt is proposed in integrated treatment strategies for the depression-cancer cycle. (PMID:41672225)
- Smartphone-based CBT interventions are discussed as a scalable alternative for helping reduce depressive symptoms. (PMID:41990254)
- A 2026 Journal of Medical Internet Research qualitative analysis (PMID:41990254) focused on evidence-based strategies in a digital mental health intervention for depression.
Traditional and Experimental Therapies
- zhi zi hou po decoction has long been used clinically for depression and was reported to ameliorate depressive-like behaviors. (PMID:41702466)
- In the 2026 Journal of Ethnopharmacology study (PMID:41702466), the decoction acted via TFAM-induced mitophagy in neurons to alleviate neuroinflammation.
- The study links depression-related behavioral improvement to a neuronal mitochondrial quality-control mechanism. (PMID:41702466)
- These findings support mechanistic exploration of traditional formulations for depression treatment. (PMID:41702466)